Kornimate/medical-research-clean huggingface dataset:
molecular mechanisms of raspberries effect on insulin resistance and inflammation

Conditions: Inflammation; Insulin Resistance

Summary: red raspberries (rubus idaeus) are a good source of health enhancing hydrolyzable and condensed tannins, flavonoids, anthocyanins, phenolic acids, rheosmin, potassium, carotenoids, vitamin c, and vitamin k1. compared to other berries commonly consumed in the us, the health benefits of red raspberries to improve pre-diabetes mellitus (pdm) and type 2 diabetes have never been explored. the clinical study proposed in this project seeks to investigate the protective effect of whole red raspberries against insulin resistance, oxidative stress, and inflammation in pdm and type 2 diabetic patients. the in vitro study proposed in the project will assist in identifying the molecular mechanisms by which whole red raspberry protect islet cells against oxidative stress, insulin resistance and loss of cell function.


Eligibility criteria:
inclusion criteria: * type 2 diabetes exclusion criteria: * hypoglycemic agents * pregnant or nursing a child * chronic medication that does not have a stable dose for greater than one month * anti-inflammatory medication * inflammatory disease
negative pressure wound therapy for wound healing after stoma reversal

Conditions: Stoma Site Infection

Summary: stoma reversal is associated with high incidence of post-surgical complications, including surgical site infections (ssi). negative pressure wound therapy (npwt) has been successfully applied to surgical wound management, reducing the ssis incidence. this is a randomized open-label trial to assess the efficacy of npwt in decreasing the rate of ssi after stoma reversal.

stoma reversal after abdominal resection is associated with several complications, of which the most common is wound infection. surgical site infections (ssi) usually result in increased long-term complications, such as incisional hernia, prolonged hospital stay, increased outpatients visits and medical costs. negative-pressure-wound-therapy (npwt) is a technique using vacuum dressing, commonly used to promote surgical wound healing, but there is a significant lack of knowledge about its safety and efficacy in promoting wound healing after stoma closure. this is an interventional, randomized, open label trial to evaluate the safety and efficacy of the npwt (pico™ system, smith\&nephew healthcare, hull, uk) on stoma wound compared to standard of care (soc).

Eligibility criteria:
inclusion criteria: * age \>18 years, any sex; * patients who underwent elective open or laparoscopic rectal resection ostomy construction (loop/end ileostomy; loop/end colostomy) for either oncological and inflammatory bowel disease (ibd) indications; * normal water contrast enema prior to surgery; * both neo-adjuvant and adjuvant treatment are allowed for cancer patients; * both immunosuppressant and biological medications are allowed for ibd patients. exclusion criteria: * patients age at screening \< 18 years; * pregnant or breastfeeding women; * neurodegenerative disorders or psychiatric diseases; * contraindications or hypersensitivity to the use of the investigational product or its components; * patients with skin features (e.g., tattoos, pre-existing scarring) which could interfere with the study assessments; * patients with post-operative bleeding (to be assessed 24 hours after surgery).

Keywords: stoma surgical site infection negative pressure wound therapy
efficacy and safety of faster-acting insulin aspart compared to novorapid® both in combination with insulin degludec in adults with type 1 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: this trial is conducted in asia, europe and north america. the purpose is to confirm efficacy in terms of glycaemic control of treatment with mealtime faster-acting insulin aspart in combination with insulin degludec in adults with type 1 diabetes mellitus.


Eligibility criteria:
inclusion criteria: - male or female, age greater than or equal to 18 years ( for japan and taiwan: age greater than or equal to 20 years) at the time of signing informed consent - type 1 diabetes mellitus (based on clinical judgement and/or supported by laboratory analysis as per local guidelines) 12 months or more prior to screening - currently treated with a basal-bolus insulin regimen for at least 12 months prior to screening (visit 1) - currently treated with a basal insulin analogue for at least 4 months prior to screening (visit 1) - hba1c 7.0-9.5% (53-80 mmol/mol) (both inclusive) as assessed by central laboratory - body mass index less than or equal to 35.0 kg/m\^2 exclusion criteria: - within the past 180 days any of the following: myocardial infarction, stroke or hospitalization for unstable angina and/or transient ischemic attack - subjects presently classified as being in new york heart association (nyha) class iv currently planned coronary, carotid or peripheral artery revascularisation - diabetic ketoacidosis requiring hospitalisation within the last 180 days prior to screening (visit 1) - treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of three months before screening (visit 1)
study measuring the safety, immunogenicity and lot consistency of cell derived influenza vaccine

Conditions: Influenza

Summary: a phase 3 study to obtain additional safety and immunogenicity data on solvay's cell-derived seasonal trivalent subunit influenza vaccine in adult and elderly subjects without significant illnesses and to demonstrate consistency of the immunogenicity of the three lots of the same vaccine, comparison of cell-derived vaccine to solvay's egg-derived vaccine including assessment of non-inferior immunogenicity


Eligibility criteria:
inclusion criteria 1. female or male subjects \>= 18 years of age (adults \>= 18 to \ = 61 years of age). 2. willing and able to give informed consent before any protocol procedures are performed. 3. able to adhere to visit schedules and all protocol required study procedures. 4. being in good health as determined by medical history, physical examination and clinical judgment of the investigator (subjects may have underlying illnesses such as hypertension, diabetes, ischemic heart disease or hypothyroidism, as long as the disease is well controlled. if on medication for a condition, the medication dose must have been stable for at least 3 months preceding study vaccination). exclusion criteria 1. influenza vaccination or laboratory confirmed influenza infection within six months preceding the date of study vaccination or planning an influenza vaccination during the three weeks after study vaccination (i.e. between study day 1 and study day 22). 2. presence of any significant condition that may prohibit inclusion as determined by the investigator. 3. a serious adverse reaction after a previous (influenza) vaccination. 4. a history of guillain-barré syndrome. 5. known to be allergic to constituents of the study vaccines.

Keywords: influenza vaccine chmp criteria
1h magnetic resonance spectroscopy in migraine patients

Conditions: Migraine Disorders; Migraine Without Aura; Headache Disorders, Primary; Headache Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Summary: to investigate the glutaminergic system in the onset of migraine-like attacks.

glyceryl trinitrate infusion (gtn) is used to provoke migraine-like attacks in female migraine without aura patients. apart from migraine without aura patients healthy female controls are also included as a control group. over the course of a single day these females (migraineurs and healthy controls) were scanned three times on fixed time slots: before gtn infusion (baseline), 90 minutes and 270 minutes after start of gtn infusion. scans are acquired on a 7 tesla scanner (philips, cleveland, usa) on software release 3 using a 32 channel receive array using single-volume proton magnetic resonance spectroscopy (1h mrs) with a volume of interest in the visual cortex glutamate, in which glutamate, gaba and other metabolites will be assessed. the primary endpoint; glutamate level changes towards the pre-ictal and ictal state with other metabolite (e.g. glutamine and gaba) changes as secondary endpoints.

Eligibility criteria:
inclusion criteria: * diagnosed with migraine without aura according to the international classification of headache disorders (ichd)-3 beta criteria from 2013. * at least one migraine attack per month in the preceding six months exclusion criteria: * other neurological disorders apart from migraine * chronic medication apart from oral contraceptives * migraine with aura * chronic migraine with 15 or more headache days per month/with 8 or more migraine days per month * medication-overuse headache (ichd-3 beta criteria) * women who are breastfeeding, pregnant, or planning to become pregnant * contra-indications for 7 tesla mri scanner * contra-indications for gtn administration (e.g. nitrate allergy, heart condition) * healthy controls (with no first degree relative with migraine or trigeminal autonomic cephalalgia)
an open-label, dose-escalation study of imc-20d7s in participants with malignant melanoma

Conditions: Malignant Melanoma

Summary: a dose-escalation study designed to determine the safety, maximum tolerated dose (mtd), anti-melanoma activity, antibody blood levels and progression-free survival (pfs) in participants with malignant melanoma receiving imc-20d7s either every 2 weeks or every 3 weeks.


Eligibility criteria:
inclusion criteria: * participant has histologically or cytologically confirmed cutaneous, mucosal, or uveal malignant melanoma which has progressed after or during at least 1 treatment with standard cytotoxic treatment or/and immunotherapy \[for example (e.g.), treatment with cytokines, monoclonal antibodies, and vaccines\] and is not regarded to be a candidate for a potentially curative, higher priority treatment for melanoma * participant is ≥18 years of age * participant has either measurable disease as defined by response evaluation criteria in solid tumors version 1.1 (recist v1.1) or evaluable disease * at least 21 days must have elapsed from major surgery, prior chemotherapy, prior treatment with an investigational agent or device, or prior radiation therapy. relative to participant's treatment with non-approved biological products (eg, monoclonal antibodies), a minimum of 2 half-lives must have passed for eligibility to be considered * participant has resolution of all clinically significant toxic effects of prior cancer therapy to grade ≤1 according to national cancer institute common terminology criteria for adverse events version 4.02 (nci-ctcae v4.02) * participant has adequate hematological function, hepatic function, and renal function exclusion criteria: * participant has undergone major surgery \[e.g., laparotomy, thoracotomy, removal of organ(s)\] within 21 days prior to study entry * participant has elective or planned surgery to be conducted during the trial * participant has documented and/or symptomatic brain or leptomeningeal metastases * participant is receiving systemic steroids or other immunosuppressive medications. (intermittent use of steroid-containing medications e.g., for asthma exacerbation or for skin lesions is permitted) * participant has an uncontrolled undercurrent illness * participant has a concurrent active malignancy other than adequately treated nonmelanomatous skin cancer or other noninvasive carcinoma or in situ neoplasm * participant has a known allergy to any of the treatment components (monoclonal antibodies or other therapeutic proteins such as fresh frozen plasma, human serum albumin, cytokines, or interleukins). in the event that there is suspicion the participant may have allergies, the participant should be excluded * participant is pregnant or lactating * participant has known human immunodeficiency virus (hiv) or acquired immune deficiency syndrome (aids) infection

Keywords: melanoma phase i antibody melanin tyrosinase related protein 1 glycoprotein 20d7s
topical application of low-concentration (0.01%) atropine on the human eye with fast and slow myopia progression rate

Conditions: Myopia

Summary: our project is a 24-month longitudinal randomized controlled trial that aims to investigate the myopia development after topical application of 0.01% atropine in children with either fast or slow myopia progression classified according to their initial electro-retinal responses. this will help elucidate the effectiveness of using low concentration atropine for myopia control in children with different myopia progression rates.


Eligibility criteria:
inclusion criteria: * age between 7 and 10 years * good general health and no family history of ocular diseases * no current or history of epilepsy or asthma * myopia : -0.50 to -1.00 d (inclusive, both eyes) * astigmatism : ≤ 0.50 d * no hyperopia, amblyopia or strabismus * no reported ocular eye diseases or disorders * no drug allergy

Keywords: myopia myopia control atropine electroretinogram multifocal electroretinogram
community based strategies for early detection of melanoma

Conditions: Melanoma

Summary: the purpose of this study is to pilot the use of community education and digital dermatology to increase the early detection of curable melanomas.


Eligibility criteria:
inclusion criteria: * 18 years and older * \>1mm lesion thickness with ulceration (t2b) or \>2mm lesion thickness (t3/t4) * low socioeconomic status (ses) non-latinx white individuals (according to yost's index ses level based on a principal components analysis) * latinx individuals * individual resides in semi-rural area, including zip codes within antelope valley in southern california and salinas in northern california * individual speaks and reads english or spanish * voluntary willingness and comprehension to consent exclusion criteria: exclusion criteria is stage 0, i, iv, or unstaged diagnosis, or any individual who does not meet the above stated eligibility criteria will be excluded from the study.
the effect of auditory and tactile stimuli in traumatic coma

Conditions: Head Trauma; Traumatic Coma; Nursing Caries

Summary: this study focused on examining the effects of auditory and tactile stimuli to reduce sensory deprivation on consciousness, oxygen saturation and mean arterial pressure in traumatic coma patients.

background: one of the most important problems experienced by patients treated in the intensive care unit due to traumatic coma is sensory deprivation. aim: in this study, it was aimed to examine the effects of auditory and tactile stimulus to be used in the prevention of sensory deprivation on consciousness, oxygen saturation and mean arterial pressure. study design: the study was planned as a randomized controlled single-blind experiment with three groups. in the study, the patients in the control group will be given a routine application, the patients in the intervention a group will be given auditory stimuli, and the patients in the intervention b group will be treated with tactile stimulus. interventions will be administered once a day for seven days, for a total of seven times. the "block randomization method" was chosen as the randomization method. in this study, hospitals were taken as a block. an equal number of patients will be recruited from two hospitals and 15 patients will be distributed to three groups from each hospital using the "simple randomization method". 30 patients in each group and 90 patients in total will be included in the study. methods: the researcher applied to the patients hospitalized in the intensive care unit for 24-72 hours for seven days, once a day (seven times in total) between 10:00 and 15:00 (intervention a: 10 minutes of audio recording will be played with headphones. intervention b: 10 minutes) (5 minutes for one foot) foot massage will be applied. glaskow coma score, oxygen saturation and mean arterial pressure will be measured before and after each intervention (twice daily).

Eligibility criteria:
inclusion criteria: * being treated in the intensive care unit for at least 24 hours due to traumatic coma, * 18 years and older * relatives of those who agreed to participate in the study * gcs score between 3-8 (gcs: 3-8 indicates coma) * without hearing impairment * having no authority for auditory stimulus * no problem for foot massage (lower extremity fracture, infection) exclusion criteria: * who are under the age of 18 * those whose relatives do not agree to participate in the research * gks score above 8

Keywords: head trauma nursing auditory stimulus tactile stimulus foot massage consciousness coma
effects of oral prednisolone on bone metabolism in patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the aim of this study is to establish associations between blood and urine markers of bone metabolism with histomorphometric changes (changes in the actual bone structure) resulting from short term oral prednisolone treatment in patients with copd (chronic obstructive pulmonary disease).


Eligibility criteria:
inclusion criteria: * females subjects must be unable to have children. * bmi 19 - 29.9 * non-smokers, ex-smokers or current light smokers (\<10 cigarettes/day) exclusion criteria: * high blood pressure * other significant disease * use of certain medications (to be decided by the investigator)

Keywords: copd prednisolone bone biopsy tetracycline labelling
efficacy and safety of furmonertinib in egfr-mutant, pd-l1+ patients with locally advanced or metastatic nsclc (future)

Conditions: Non-Small-Cell Lung Cancer

Summary: the aim of this phase ⅱ study is to evaluate the efficacy and safety of furmonertinib in egfr-mutant, pd-l1+ patients with locally advanced or metastatic nsclc.


Eligibility criteria:
inclusion criteria: 1. male or female subjects aged ≥18 years old; 2. locally advanced or metastatic non-squamous non-small cell lung cancer confirmed by histology or cytology (stage ⅲb-ⅳ, according to the 8th edition of the ajcc staging system); 3. the tumour harbours one of the most common egfr mutations (19del or l858r); 4. the programmed death-ligand 1 (pd-l1) tumoral expression is positive; 5. no previous systemic anti-tumor therapy for locally advanced or metastatic nsclc; 6. according to recist 1.1, subjects have at least one measurable tumor lesion at baseline; 7. ecog performance status score 0-2； 8. subjects have voluntarily participated, signed and dated informed consent. exclusion criteria: 1. lung squamous carcinoma (including adenosquamous carcinoma and undifferentiated carcinoma) and small cell lung cancer; 2. subjects have no measurable tumor lesion at baseline; 3. subjects with spinal cord compression or symptomatic brain metastases; 4. subjects are suitable for surgery; 5. previous therapy with platinum-based chemotherapy, egfr-tkis, or anti-pd1/pd-l1 agents; 6. aspartate aminotransferase (ast) and/or alanine aminotransferase (alt)\>2.5 × uln, or serum total bilirubin (tbil)\>1.5 × uln, or cr\>1.0×uln; 7. absolute value of neutrophil (anc)\<1.5 × 109/l, or platelet (plt) count\<75 × 109/l, or hemoglobin (hgb)\<90 g/l; 8. any of the following disease within 12 months: myocardial infarction, severe/unstable stenocardia, coronary/peripheral artery bypass grafting, symptomatic congestive heart failure, or cerebrovascular accident; 9. women who are pregnancy or lactation, or fertile but not using contraception; 10. suffering from other serious acute or chronic physical or mental problems; 11. subjects who are considered ineligible for the study for other reasons according to the investigator's assessment.
silodosin in management of lower ureteral stones

Conditions: Stone, Kidney

Summary: this research aims to study the effectiveness of silodosin in the management of lower ureter stones larger than 6 mm in diameter in terms of affected ureter (right or left), the size of the stone, the degree of hydronephrosis, the rate of stone expulsion(day), whether the stone was completely expelled or not, and the side effects of silodosin.


Eligibility criteria:
inclusion criteria: * patients attending the urology clinic with a distal unilateral ureteral stone larger than 6 mm in diameter. exclusion criteria: * patients under 18 years of age * pregnant women * patients with whom we were unable to contact * patients treated with silodosin for another reason * single kidney patients * patients with bilateral ureter stones * patients with deteriorating kidney function * patients with grades 3rd and 4th of hydronephrosis

Keywords: silodosin lower ureteral ureteral stones
a comparison between the efficacy of modified thoracoabdominal plane block via perichondral approach (m-tapa) and external oblique intercostal plane block (eoipb) in patients undergoing laparoscopic cholecystectomy surgeries (lc)

Conditions: Post Operative Pain

Summary: because laparoscopic procedures have a number of benefits over open procedures, they have completely changed the surgical industry.(1) laparoscopic cholecystectomy (lc) is a minimally invasive technique that usually yields less discomfort following surgery, shorter hospital stays, and quicker patient recovery, plus it's an economical operation. nevertheless, it results in moderate to severe pain.(2).by using regional anesthesia techniques to effectively control pain and lessen the requirement for opioid analgesics, eras implementation has demonstrated significant decreases in opioid usage and improved overall patient outcomes (3). (4) to minimize the need for opioids, opioid sparing anesthesia employs a multimodal strategy that includes nonsteroidal anti-inflammatory medications, paracetamol, local anesthetics (la), and, if feasible, regional anesthetic techniques and regional analgesia. (5) with fewer systemic side effects, regional anesthetic techniques-like nerve blocks-offer tailored pain treatment. the best regional pain management strategy for lc surgery is still unknown, though.(4) modified thoracoabdominal nerves block through perichondral approach (m-tapa) block is a new technique defined as a modification of tapa block in which local anaesthetics are administered only to the underside of the perichondral surface, creating a sensory block between t5-t12 dermatomes. while the external oblique intercostal plane (eoipb) block provides blockade of the lateral and anterior cutaneous branches of the intercostal nerves from t6/7 to t10/11.this study aims to compare the efficacy of both mtapa and eoipb in patients undergoing lc surgery .


Eligibility criteria:
inclusion criteria: * adults aged 18-65 years * scheduled for laparoscopic cholecystectomy surgery * asa (american society of anaesthesiologists) physical status i-ii exclusion criteria: * known allergy to local anaesthetics * coagulopathy or anticoagulant use * infection at the site of block * chronic pain conditions * advanced liver or kidney failure * history of abdominal surgery or trauma * alcohol or drug use * refusal to participate * chronic opioid consumption * use of painkillers in the preoperative 24hours * conversion to open surgery * body mass index ( bmi ) \> 35

Keywords: postoperative pain